Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Expenses (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Operating Expenses for 12 consecutive years, with $26.6 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses rose 15.61% year-over-year to $26.6 million; the TTM value through Mar 2026 reached $149.8 million, up 72.95%, while the annual FY2025 figure was $146.2 million, 76.55% up from the prior year.
  • Operating Expenses hit $26.6 million in Q1 2026 for Cartesian Therapeutics, down from $79.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $79.6 million in Q4 2025 and bottomed at $18.0 million in Q3 2024.
  • Average Operating Expenses over 5 years is $27.3 million, with a median of $23.2 million recorded in 2022.
  • Year-over-year, Operating Expenses plummeted 41.76% in 2024 and then skyrocketed 206.43% in 2025.
  • Cartesian Therapeutics' Operating Expenses stood at $25.3 million in 2022, then skyrocketed by 76.34% to $44.6 million in 2023, then tumbled by 41.76% to $26.0 million in 2024, then surged by 206.43% to $79.6 million in 2025, then plummeted by 66.61% to $26.6 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $26.6 million, $79.6 million, and $21.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.